Recent data from our group and others has found that higher frequencies and total numbers of infused effector-memory CD8+ T cells correlated highly with clinical response suggesting that CD8+ T cells in the TIL infusion product are the most critical T cells mediating objective tumor regression [1], [3], [10]. Here, CD8A is linked to neoplasm.